Окончательный рост у дево­чек с синдромом Тернера, получавших лечение гормоном роста. Анализ международной базы данных мониторинга роста фирмы «Каби Фармация» (КИГС)

Abstract

The completion of growth, which is determined in this study by slowing down the growth rate below 1 cm per year, was observed only in 15 of 640 treated with growth hormone (GH) girls with Turner syndrome (ST), information about which is included in the KIGS database. GH was administered to patients at a dose that ranged within the group within 0.3–1.0 IU / kg per week, with a multiplicity of 3 to 7 injections per week. The results of the study were presented graphically for each patient. At the beginning of GR therapy, the standard deviation index (SDS) of growth ranged from -2.4 to 1.5 compared with the standards for CT patients developed by M. Ranke. At the beginning of the study, the group indices of median, maximum and minimum SDS growth were 0.3, -2.4 and 1.5, respectively, and by the time the final growth was achieved, their increase was noted to 1.1, -1.8 and 2.7 respectively. The final growth in girls with ST ranged from 132.7 to 161.1 cm. Compared with the predicted growth calculated for each patient, changes in the final growth in the treatment of GH in combination with oxandrolone and ethinyl estradiol ranged from -0.9 to 11.9 cm (median - 5.4 cm), while in the treatment of GH in combination with ethinyl estradiol, the median indicator was 1.6 cm. For the whole group as a whole, the median of final growth was 150.4 cm, in the subgroup of patients treated with GH in combination with oxandrolone and ethinyl estradiol, 152.1 cm and in girls, receiving GH and ethinyl estradiol, 149.3 cm.